AuMEGA Metals Limited (ASX: AAM) has reported a standout result from its July airborne time-domain EM survey over Cape Ray: the work both maps known mineralisation at Central Zone and—critically—defines a large, previously untested conductor just 500 m to the southeast that mirrors Central Zone’s geophysical signature. With a fully funded drilling program slated for Q4 2025, the discovery pipeline at Cape Ray continues to expand.

Terra Critical Minerals Limited (ASX: T92) has confirmed a new high-grade silver discovery at the Silent Grove Prospect within its 100%-owned Mole River Project in New South Wales (Figure 1). This update represents an important step forward in unlocking the polymetallic potential of the Mole Granite district, an area already known for tin, tungsten, and silver-rich systems.

DY6 Metals Ltd (ASX: DY6) has delivered a practical operational update across its Malawian projects (Figure 1), completing follow-up surface sampling at Tundulu and commencing a new grid-based program at Machinga. The work targets high-value mineralisation in gallium (Ga), rare earth elements (REEs), niobium (Nb) and phosphate, with assays in preparation for SGS Randfontein.

Kaiser Reef Limited (ASX: KAU) has marked its first full quarter since acquiring the Henty Gold Mine, with reconciled production reported for 1 July–30 September 2025. Alongside the steadying of Henty as the core asset, the quarter featured renewed activity at Maldon and a strategic transition at A1, setting a clearer operational footing across the portfolio.

When Race Oncology Limited’s (ASX: RAC) share price doubled at the start of last week, many investors were left asking the same question – what just happened? The answer, as is often the case with biotech catalysts, lies in a combination of significant scientific developments, strong IP positioning, and a clear signal to the market that management is preparing for the next stage of value creation.

Key Investment Trends That has shaped Investor Opportunities ASX in 2025.

Thunderbird Resources Limited (ASX: THB) has executed a binding agreement to acquire 100% of the Springfield Gold Deposit in central NSW (Figure 1) — a project with historical shallow drilling, multiple thick, high-grade intercepts, and significant exploration upside. Alongside this acquisition, Thunderbird has secured $2.2M through a placement at $0.014/share, ensuring it is well-funded to accelerate its exploration programs.

On 25 July 2025, Opyl Limited (ASX: OPL) officially rebranded to Pathkey.AI (ASX: PKY) – a move signalling a sharpened focus on applying artificial intelligence to the most critical challenges in clinical trials and drug development. Rather than being “just another med-tech rebrand,” Pathkey.AI represents a company building a sophisticated decision-support ecosystem designed to help therapies get to patients faster, de-risk trials for sponsors, and improve capital efficiency

Founded in Christchurch, New Zealand, in 1984, Ryman Healthcare (NZX: RYM) has grown into one of Australasia’s leading operators of retirement villages and aged care services (Figure 1). For over forty years, the company’s guiding principle has been simple yet powerful — that everything it does must be “good enough for mum and dad.” This philosophy has shaped Ryman’s reputation as a trusted brand, built around its purpose of enhancing freedom, connection, and well-being for o

OD6 Metals (ASX: OD6) has wrapped up its CPC Optioneering Study—backed by ANSTO testwork—and selected a preferred process flowsheet for the clay-hosted rare earths at Splinter Rock. The decision lifts confidence that OD6 can produce low-impurity MREC/MREH products and moves the project into large-scale optimisation at ANSTO alongside the commencement of mining studies at the Inside Centre Deposit